Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$275.00K$275.00Kderived−13.0% vs Q4 2015 Net Income-$2.68M-$2.68MderivedN/M vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$2,754,000N/M Operating Cash Flowderived-$2,822,000N/M Free Cash Flowderived-$2,882,000N/M Margins · derivedOperating margin-1001.5%−401.5 pt vs Q4 2015
Net margin-973.5%−376.9 pt vs Q4 2015
ended Jun 30, 2016 · filed Oct 13, 2016 · 105 d after period end